WO2014072984A1 - Improved process for isolation and purification of rapamycin from fermentation broth - Google Patents
Improved process for isolation and purification of rapamycin from fermentation broth Download PDFInfo
- Publication number
- WO2014072984A1 WO2014072984A1 PCT/IN2012/000728 IN2012000728W WO2014072984A1 WO 2014072984 A1 WO2014072984 A1 WO 2014072984A1 IN 2012000728 W IN2012000728 W IN 2012000728W WO 2014072984 A1 WO2014072984 A1 WO 2014072984A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- process according
- tautomer
- purity
- solvent
- Prior art date
Links
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 106
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 104
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000000855 fermentation Methods 0.000 title claims abstract description 22
- 230000004151 fermentation Effects 0.000 title claims abstract description 22
- 238000000746 purification Methods 0.000 title claims abstract description 13
- 238000002955 isolation Methods 0.000 title claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002028 Biomass Substances 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 239000012141 concentrate Substances 0.000 claims abstract description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 43
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- OPFTUNCRGUEPRZ-QLFBSQMISA-N Cyclohexane Natural products CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 claims description 2
- 238000003818 flash chromatography Methods 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims 2
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 claims 1
- 238000013375 chromatographic separation Methods 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 15
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract description 10
- 238000004587 chromatography analysis Methods 0.000 abstract description 6
- 239000000843 powder Substances 0.000 description 19
- 239000012535 impurity Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000010828 elution Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 238000010908 decantation Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000012485 toluene extract Substances 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- VJYFKVYYMZPMAB-UHFFFAOYSA-N ethoprophos Chemical compound CCCSP(=O)(OCC)SCCC VJYFKVYYMZPMAB-UHFFFAOYSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007483 microbial process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Definitions
- the present invention relates to isolation and recovery of rapamycin using decanter centrifuge technology and normal phase chromatography.
- the invention also relates to purification of rapamycin in a substantially pure form with a tautomer impurity of less than 0.5%.
- Rapamycin is a macrocyclic triene antibiotic produced naturally by Streptomyces hygroscopicus. It has been found useful in an array of applications based on its antitumoral and immunosuppressive effects.. Rapamycin and its derivatives continue to be studied for treatment of these disorders.
- Rapamycin (US patent 4885171 has been shown to have antitumor activity.
- US 5616595 discloses a process for recovering water insoluble compounds (including FK506, FK520 and rapamycin) from a fermentation broth which includes sequential steps of concentrating, solubilising and diafiltrating the compound of interest, all through a single closed recirculation system to isolate the compound for further downstream purification.
- water insoluble compounds including FK506, FK520 and rapamycin
- US5508398 discloses a process for separating a neutral non-polypeptide macrolide from acidic, basic and non polar impurities present in a concentrate of fermentation broth extracts containing neutral macrolide by selective solubility.
- Use of silver for separating cis-trans isomers of an unsaturated aliphatic acid having same number of carbon atoms is known through J. Chromatography, 149, 417-419(1978).
- PCT application WO 05/019226 discloses a process for recovery of a macrolide by treating with water immiscible solvent, followed by mixing with water miscible solvent, performing hydrophobic interaction chromatography, extracting the fraction containing macrolide with water-immiscible solvent and then performing silica gel chromatography to obtain the macrolide.
- US patent application No 2004/0226501 discloses a method of crystallizing a macrolide from a concentrate of whole broth extraction containing macrolide biomatter, by combining the macrolide, a polar solvent like ethyl acetate, hydrocarbons solvent like n- hexane and sodium hydroxide to attain a pH of 7 or above.
- the methods known in the prior art do not disclose isolation of rapamycin by decanter centrifuge technique and the process literature methods known for purification of rapamycin do not result in pure form of the product.
- the present invention provides decanter centrifuge technique which is less tedious, industrially scalable efficient process, involving less solvent consumption and substantially improved yields.
- Rapamune (R) (Wyeth - brand name for the drug product) revealed the existence of three isomeric forms isomer A (cis), isomer B (rapamycin), Isomer C (trans) and other unidentified impurities.
- the present invention provides rapamycin in substantially pure form and a process to obtain the same.
- the invention discloses a process of obtaining rapamycin with an impurity content of less than 0.8% excluding Isomer C (tautomer).
- the Isomer C (tautomer) which is a major hurdle in conversion of rapamycin derivatives like temsirolimus and everolimus etc obtained less than 0.5% at 1.1 RRT.
- the invention relates to a process for isolation and purification of rapamycin from fermentation broth, comprising the steps of;
- the purification process includes treatment of rapamycin with isopropyl ether and/or diethyl ether to yield a purified rapamycin product. This is precipitated, collected by filtration, washed and then dried under vacuum in to yield a product of about 97% purity.
- step (d) is loaded on a flash chromatographic column and the final product with total impurity content of less than 0.8% and tautomer content less than 0.5% is isolated.
- FIG 1 Diagrammatic representation of a decanter centrifuge.
- FIG 2 Standard chromatogram of Rapamycin
- FIG 3 Chromatogram of crude rapamycin
- FIG 4 Chromatogram of purified rapamycin with isopropyl ether crystallization
- FIG 5 Chromatogram of purified rapamycin with diethyl ether crystallization
- FIG 6 Chromatogram of substantially pure form of rapamycin.
- the process of the present invention is directed towards recovering water insoluble compound rapamycin that is produced by large scale fermentation.
- "Recovering” as used here in refers to the process of removing related impurities from the compound of interest and encompasses removing excess fluid and dissolved soluble impurities.
- Rapamycin containing biomatter can be the starting material for practice of the present invention. Fermented broth is obtained by a microbial process using a rapamycin producing microorganism MTCC 5681. In most circumstances and particularly large scale industrial fermentations, the culture medium and fermentation conditions (strain of organism, type of inoculums, time of fermentation, fermentation temperature etc) are optimized to produce maximum yield of the desired product.
- the pH of the fermentation broth is adjusted to below 7 preferably 4.0 to 7.0 before separating mycelia.
- the acid can be organic or inorganic including hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid and formic acid etc.
- the pH adjustment is useful to remove residual soluble contaminants during separation of mycelia.
- the mycelia are' separated by centrifugal decantation technique. Centrifugal decantation refers to the process of passing fermentation broth for separating solids from liquids using a special equipment known as a Decanter Centrifuge in one single continuous process (Fig 1 ). This is done by centrifugal force.
- the solid mass after centrifugal decantation is mixed with a solvent capable of solubilising the compound of interest to form liquid slurry.
- Solvents useful in the present invention include alcohols (C 4 to C 6 ), esters of lower alcohols (C ⁇ to C 6 ), chlorinated hydrocarbons and lower ketones (C 3 to C 6 ).
- Preferred extraction solvents are isobutyl acetate, n-butyl acetate, t-butyl acetate, ethyl acetate, propyl acetate, ethyl formate, dichloromethane, chloroform, carbon tetra chloride and toluene.
- Toluene and ethyl acetate are particularly preferred hydrophobic extraction solvents. Those skilled in the art can easily select a suitable solvent knowing the physic chemical properties of the rapamycin.
- Extraction can be carried out at any convenient temperature between 2°C about 70°C. Preferably the extraction is carried out at a temperature about 25°C and about 50°C. The skilled artisan will know to optimize the extraction time depending on the macrolide containing biomass, hydrophobic extraction solvent, equipment used and temperature. At the end of the extraction, the extraction mixture contains rapamycin in the extraction solvent as well as residual extracted biomass.
- the amount of solvent used is generally atleast twice the amount of solid biomass after the centrifugal decantation. Typically two to six equivalent volumes are used.
- the impurities may be present in the solid or liquid. The impurities can be separated by filtration, phase separation or both.
- the organic layer rich in rapamycin is washed with base and water. Then activated charcoal is added and filtered.
- the base can be selected from inorganic or organic bases. Preferably, the base can be aqueous sodium bicarbonate.
- rapamycin in hydrophobic solvent is concentrated to an oily residue.
- the concentration can be at atmospheric pressure or it can be at reduced pressure, attained with the aid of vacuum pump or water aspirator.
- the concentration is preferably carried out at a temperature above 25°C. The concentration is carried out until the volume of the rapamycin containing solvent is reduced to about 0.5 to 1 % of its initial volume, or less to provide concentrated rapamycin as an oily residue. Crude rapamycin can be isolated
- oily residue containing rapamycin is purified by column chromatography on a silica gel column.
- the mixture of rapamycin and analogous compounds are dissolved in a suitable solvent and subjected to column chromatography using silica gel having mesh size of 60 - 200.
- the mixture is adsorbed on the column and is successively eluted with organic solvents.
- the fractions rich in rapamycin can be pooled to recover rapamycin.
- the organic solvent for elution can be for example an aliphatic hydrocarbon, a C 2- i 0 ester, a chlorinated hydrocarbon, ketone, C 4-8 ethers or mixtures thereof.
- the C 2 -io esters can be for example ethyl acetate, iso butyl acetate and n-butyl acetate etc.
- Aliphatic hydrocarbons can be for example n-pentane, n-hexane, n- heptane and cyclo hexane etc.
- Aliphatic ketone can be for example acetone, 2-butanone etc.
- the eluant can be isocratic, that is of constant composition or the composition of the eluant can be varied during elution. Preferred eluants include mixtures of acetone and hexane.
- crude rapamycin as used here in refers to a rapamycin powder that contains less than about 10% impurities including the tautomer.
- Another aspect of the present invention relates to a method for purifying rapamycin by crystallization (precipitation) and includes i) Dissolving crude rapamycin in isopropyl ether ii) Mixing over a period of 2-3hrs . iii) Filtering the product to obtain rapamycin powder, iv) Washing the rapamycin powder with chilled isopropyl ether and v) drying the product.
- the obtained rapamycin powder contains less than about 5% impurities including tautomer.
- a method for purifying rapamycin includes; i) Dissolving rapamycin powder with a purity of about 90% in diethyl ether, ii) Mixing over a period of 2-3hrs. iii) Filtering the product to obtain rapamycin powder, iv) Washing the rapamycin powder with chilled diethyl ether and v) Drying the product.
- the obtained rapamycin powder contains less than 1.5% impurities excluding tautomer and tautomer content is less than 2%.
- the purified product by crystallization from isopropyl ether and/or diethyl ether may be further purified with a suitable chromatographic medium.
- the present invention also relates to a method for purification of rapamycin in substantially purified form using flash chromatographic technique.
- the stationary phase can be silica with particle size of about 40 ⁇ with a narrow range of size distribution. Using this silica, resolution of closely eluting compounds dramatically increased and also yields fractions of high purity with improved loading capacity. Thereby reduction in solvent consumption is achieved.
- the elution is carried out using an organic solvent selected from a group comprising acetone, ethyl acetate, hexane, diethyl ether.
- the elution is carried out with ethyl acetate and hexane.
- the pure rapamycin powder thus obtained contains total impurity content less than 0.8% excluding tautomer.
- the tautomer content obtained is less than 0.5% at 1.1 relative retention time (RRT) with rapamycin purity of about 99% (HPLC).
- the present invention relates to rapamycin with total impurity content less than 0.8%.by HPLC excluding tautomer.
- the present invention also relates to rapamycin with tautomer content less than 0.5% at 1.1 RRT. All RRTs are here with respect to rapamycin retention time (R.T).
- the purity of rapamycin thus obtained is more than 99%.
- the details of HPLC method for analysis of crude and purified forms of rapamycin in the present invention are as follows:
- the identity of the product isolated and purified was confirmed as rapamycin through comparison of physic-chemical, spectral and chromatographic properties with those of a sample of authentic rapamycin.
- the purity of the product was determined by high pressure liquid chromatographic analysis.
- rapamycin fermentation broth obtained a large scale fermentation experiment was acidified by addition of dil. sulphuric acid to pH 4.0.
- the acidified broth containing 5.1% dried solids and 50% of suspended wet solids were fed into a receiver tank.
- the decanter centrifuge (Fig- 1) consists of centrifuge, conveyer assembly, bowl assembly and frame and casing assembly (ALDEC 20, Alfa laval, Sweden).
- the feed flow rate was set at lm 3 /hr and the broth was pumped through a stationary feed inlet tube.
- the centrifuge was operated with bowl speed of 4400 rpm at 3030 G (centrifugal force).
- the oily residue (3kg) was applied to a column packed with 30kg of silica gel of 60 - 200 mesh size. The column diameter was 250mm and length was 1.5m.
- the elution was carried out with gradient mobile phase of acetone and hexane (90% hexane, 10% acetone - 60 It, 80% hexane, 20% acetone - 60 Its, 70% hexane, 30% acetone - 60 It, 60% hexane, 40% acetone— 150 It).
- the drug rich fractions were eluted at 60% hexane, 40% acetone ratio.
- the collected fractions were mixed with 5.25g of activated charcoal. The solution was stirred, filtered and concentrated under vacuum at 40°C. The residue was dried to obtain 400g of crude powder .
- the rapamycin purity was 90% with tautomer content 6.5% at 1.1 RRT and other impurities 3.5%.
- Rapamycin powder (lOg) obtained from example 3 was dissolved in 30ml of isopropyl ether. The solution was stirred, filtered and concentrated at 25°C. The crystals were dried to obtain 9g of white rapamycin powder. The purity of rapamycin powder was 95% with tautomer content of 2.5% at 1.1 RRT and other impurities amounting to 2.5%.
- Rapamycin powder (5g) obtained from example 3 was dissolved in 10ml of diethyl ether. The solution was stirred, filtered and concentrated at 25°C. The crystals were dried to obtain 4.0g of white rapamycin powder. The purity of rapamycin powder was 97% with tautomer content of 1.5% at 1.1 RRT, and other impurities amounting to 1.5%.
- Rapamycin powder (lOOmg) obtained from example 4 was dissolved in 200ml of acetone. The solution was loaded on a column packed with flash specific media (cartridge from Grace Company, diameter 0.81cm, particle size 40 ⁇ , height 9.6cm). The product was eluted by gradient method.
- the product was eluted at a ratio of 60% hexane, 40% acetone and 58% hexane, 42% acetone.
- the fractions containing pure rapamycin were pooled and concentrated at 15°C.
- the crystals were filtered and dried. 50mg of rapamycin powder was obtained. .
- the purity of rapamycin powder was 99% with tautomer content 0.4% at RRT 1.1 and 0.6% of other impurities.
- the HPLC chromatograms for rapamycin (reference standard) and that of rapamycin produced in substantially pure form as above using flash chromatography are shown in Fig 2 and Fig 6 respectively.
- the details of chromatogram as in fig 2 are given in Table 6 and that of fig6 is given in Table 7.
Abstract
The present invention relates to a novel process for the isolation of water insoluble macrolide antibiotic rapamycin from the fermentation broth through sequential steps of biomass separation, extraction with suitable solvents and concentration. The invention also relates to separating rapamycin from the concentrate containing a mixture of homologs, analogs or isomers thereof by using normal phase chromatography followed by purification.
Description
IMPROVED PROCESS FOR ISOLATION AND PURIFICATION OF RAPAMYCIN FROM FERMENTATION BROTH
FIELD OF THE INVENTION
The present invention relates to isolation and recovery of rapamycin using decanter centrifuge technology and normal phase chromatography. The invention also relates to purification of rapamycin in a substantially pure form with a tautomer impurity of less than 0.5%. BACKGROUND OF THE INVENTION
Rapamycin is a macrocyclic triene antibiotic produced naturally by Streptomyces hygroscopicus. It has been found useful in an array of applications based on its antitumoral and immunosuppressive effects.. Rapamycin and its derivatives continue to be studied for treatment of these disorders.
Rapamycin, its preparation and its antibiotic activity were described in U.S. patent no 3929992.
Rapamycin (US patent 4885171 has been shown to have antitumor activity.
US 5616595 discloses a process for recovering water insoluble compounds (including FK506, FK520 and rapamycin) from a fermentation broth which includes sequential steps of concentrating, solubilising and diafiltrating the compound of interest, all through a single closed recirculation system to isolate the compound for further downstream purification.
US5508398 discloses a process for separating a neutral non-polypeptide macrolide from acidic, basic and non polar impurities present in a concentrate of fermentation broth extracts containing neutral macrolide by selective solubility.
Use of silver for separating cis-trans isomers of an unsaturated aliphatic acid having same number of carbon atoms is known through J. Chromatography, 149, 417-419(1978).
PCT application WO 05/019226 discloses a process for recovery of a macrolide by treating with water immiscible solvent, followed by mixing with water miscible solvent, performing hydrophobic interaction chromatography, extracting the fraction containing macrolide with water-immiscible solvent and then performing silica gel chromatography to obtain the macrolide. US patent application No 2004/0226501 discloses a method of crystallizing a macrolide from a concentrate of whole broth extraction containing macrolide biomatter, by combining the macrolide, a polar solvent like ethyl acetate, hydrocarbons solvent like n- hexane and sodium hydroxide to attain a pH of 7 or above. The methods known in the prior art do not disclose isolation of rapamycin by decanter centrifuge technique and the process literature methods known for purification of rapamycin do not result in pure form of the product.
The present invention provides decanter centrifuge technique which is less tedious, industrially scalable efficient process, involving less solvent consumption and substantially improved yields.
The HPLC analysis of Rapamune(R) (Wyeth - brand name for the drug product) revealed the existence of three isomeric forms isomer A (cis), isomer B (rapamycin), Isomer C (trans) and other unidentified impurities.
The present invention provides rapamycin in substantially pure form and a process to obtain the same. The invention discloses a process of obtaining rapamycin with an impurity content of less than 0.8% excluding Isomer C (tautomer). The Isomer C
(tautomer) which is a major hurdle in conversion of rapamycin derivatives like temsirolimus and everolimus etc obtained less than 0.5% at 1.1 RRT.
BRIEF DISCLOSURE OF THE INVENTION
Briefly the invention relates to a process for isolation and purification of rapamycin from fermentation broth, comprising the steps of;
1. Adjusting the pH of the fermentation broth to 4.0 and concentrating by centrifugal decanter.
2. To the concentrated biomatter containing rapamycin, addition of hydrophobic extraction solvent where extraction temperature is between 35 to 45°C. The Solvent extract is evaporated under reduced pressure to yield oily residue containing crude rapamycin.
3. Isolation of crude rapamycin by adsorbing on silica gel from a solution in a non polar solvent, followed by elution therefrom with a second solvent more polar than the first solvent.
4. The purification process includes treatment of rapamycin with isopropyl ether and/or diethyl ether to yield a purified rapamycin product. This is precipitated, collected by filtration, washed and then dried under vacuum in to yield a product of about 97% purity.
5. The product from step (d) is loaded on a flash chromatographic column and the final product with total impurity content of less than 0.8% and tautomer content less than 0.5% is isolated.
Other aspects and advantages of the invention will be apparent from the following detailed description.
BRIEF DESCRIPTION OF DRAWINGS
FIG 1 : Diagrammatic representation of a decanter centrifuge.
FIG 2: Standard chromatogram of Rapamycin
FIG 3: Chromatogram of crude rapamycin
FIG 4: Chromatogram of purified rapamycin with isopropyl ether crystallization
FIG 5: Chromatogram of purified rapamycin with diethyl ether crystallization
FIG 6: Chromatogram of substantially pure form of rapamycin.
DETAILED DESCRIPTION OF THE INVENTION
The process of the present invention is directed towards recovering water insoluble compound rapamycin that is produced by large scale fermentation. "Recovering" as used here in refers to the process of removing related impurities from the compound of interest and encompasses removing excess fluid and dissolved soluble impurities. Rapamycin containing biomatter can be the starting material for practice of the present invention. Fermented broth is obtained by a microbial process using a rapamycin producing microorganism MTCC 5681. In most circumstances and particularly large scale industrial fermentations, the culture medium and fermentation conditions (strain of organism, type of inoculums, time of fermentation, fermentation temperature etc) are optimized to produce maximum yield of the desired product.
At the cessation of the fermentation, the pH of the fermentation broth is adjusted to below 7 preferably 4.0 to 7.0 before separating mycelia. The acid can be organic or inorganic including hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid and formic acid etc. The pH adjustment is useful to remove residual soluble contaminants during separation of mycelia.
In the process after acidification of the fermentation broth, the mycelia are' separated by centrifugal decantation technique. Centrifugal decantation refers to the process of passing fermentation broth for separating solids from liquids using a special equipment known as a Decanter Centrifuge in one single continuous process (Fig 1 ). This is done by centrifugal force. When the fermentation broth passes through the unit, the centrifugal force compact the solids and expels surplus liquids. The dried solids are discharged from the bowl. The clarified aqueous liquid phase is then separated by flow path. The water insoluble compound of interest remains in the dried solids. Removal of mycelial solids and separation of liquids are crucial function in a fermentation process. This type of decanter centrifuge is most useful and preferred when the solid content in the fermentation broth exceeds more than 65% (w/v).
It has been found that the separation of mycelia and isolation of rapamycin into solvent leads to near quantitative recovery from the fermentation broth.
In the second step of the present invention, the solid mass after centrifugal decantation is mixed with a solvent capable of solubilising the compound of interest to form liquid slurry. Solvents useful in the present invention include alcohols (C4 to C6), esters of lower alcohols (C\ to C6), chlorinated hydrocarbons and lower ketones (C3 to C6). Preferred extraction solvents are isobutyl acetate, n-butyl acetate, t-butyl acetate, ethyl acetate, propyl acetate, ethyl formate, dichloromethane, chloroform, carbon tetra chloride and toluene. Toluene and ethyl acetate are particularly preferred hydrophobic extraction solvents. Those skilled in the art can easily select a suitable solvent knowing the physic chemical properties of the rapamycin.
Extraction can be carried out at any convenient temperature between 2°C about 70°C. Preferably the extraction is carried out at a temperature about 25°C and about 50°C. The skilled artisan will know to optimize the extraction time depending on the macrolide containing biomass, hydrophobic extraction solvent, equipment used and temperature. At
the end of the extraction, the extraction mixture contains rapamycin in the extraction solvent as well as residual extracted biomass.
The amount of solvent used is generally atleast twice the amount of solid biomass after the centrifugal decantation. Typically two to six equivalent volumes are used. The impurities may be present in the solid or liquid. The impurities can be separated by filtration, phase separation or both. The organic layer rich in rapamycin is washed with base and water. Then activated charcoal is added and filtered. The base can be selected from inorganic or organic bases. Preferably, the base can be aqueous sodium bicarbonate. Following the extraction, rapamycin in hydrophobic solvent is concentrated to an oily residue. The concentration can be at atmospheric pressure or it can be at reduced pressure, attained with the aid of vacuum pump or water aspirator. The concentration is preferably carried out at a temperature above 25°C. The concentration is carried out until the volume of the rapamycin containing solvent is reduced to about 0.5 to 1 % of its initial volume, or less to provide concentrated rapamycin as an oily residue. Crude rapamycin can be isolated from the oily residue.
In the third step of the present invention, oily residue containing rapamycin is purified by column chromatography on a silica gel column. The mixture of rapamycin and analogous compounds are dissolved in a suitable solvent and subjected to column chromatography using silica gel having mesh size of 60 - 200. The mixture is adsorbed on the column and is successively eluted with organic solvents. The fractions rich in rapamycin can be pooled to recover rapamycin. The organic solvent for elution can be for example an aliphatic hydrocarbon, a C2-i0 ester, a chlorinated hydrocarbon, ketone, C4-8 ethers or mixtures thereof. The C2-io esters can be for example ethyl acetate, iso butyl acetate and n-butyl acetate etc. Aliphatic hydrocarbons can be for example n-pentane, n-hexane, n- heptane and cyclo hexane etc. Aliphatic ketone can be for example acetone, 2-butanone etc. The eluant can be isocratic, that is of constant composition or the composition of the
eluant can be varied during elution. Preferred eluants include mixtures of acetone and hexane.
After the concentration of the fractions containing crude rapamycin, the product may optionally be processed further by crystallization and/or chromatography. The term crude rapamycin as used here in refers to a rapamycin powder that contains less than about 10% impurities including the tautomer.
Another aspect of the present invention relates to a method for purifying rapamycin by crystallization (precipitation) and includes i) Dissolving crude rapamycin in isopropyl ether ii) Mixing over a period of 2-3hrs . iii) Filtering the product to obtain rapamycin powder, iv) Washing the rapamycin powder with chilled isopropyl ether and v) drying the product. The obtained rapamycin powder contains less than about 5% impurities including tautomer.
In a further aspect, a method for purifying rapamycin is provided by recrystallization and includes; i) Dissolving rapamycin powder with a purity of about 90% in diethyl ether, ii) Mixing over a period of 2-3hrs. iii) Filtering the product to obtain rapamycin powder, iv) Washing the rapamycin powder with chilled diethyl ether and v) Drying the product. The obtained rapamycin powder contains less than 1.5% impurities excluding tautomer and tautomer content is less than 2%. As a further aspect of the invention, the purified product by crystallization from isopropyl ether and/or diethyl ether may be further purified with a suitable chromatographic medium. The present invention also relates to a method for purification of rapamycin in substantially purified form using flash chromatographic technique. The stationary phase can be silica with particle size of about 40μπι with a narrow range of size distribution.
Using this silica, resolution of closely eluting compounds dramatically increased and also yields fractions of high purity with improved loading capacity. Thereby reduction in solvent consumption is achieved. The elution is carried out using an organic solvent selected from a group comprising acetone, ethyl acetate, hexane, diethyl ether. Preferably the elution is carried out with ethyl acetate and hexane. The pure rapamycin powder thus obtained contains total impurity content less than 0.8% excluding tautomer. The tautomer content obtained is less than 0.5% at 1.1 relative retention time (RRT) with rapamycin purity of about 99% (HPLC). The present invention relates to rapamycin with total impurity content less than 0.8%.by HPLC excluding tautomer. The present invention also relates to rapamycin with tautomer content less than 0.5% at 1.1 RRT. All RRTs are here with respect to rapamycin retention time (R.T). The purity of rapamycin thus obtained is more than 99%. The details of HPLC method for analysis of crude and purified forms of rapamycin in the present invention are as follows:
Column: UNISON UK C 18, 3μηι, diameter - 4.6mm, length - 250mm
Flow rate: l .Oml/min
Detection wave length: 280nm
Injection volume: 20μ1
Diluent: Methanol
Temperature: 55°C
Approximate retention time (RT) of rapamycin: 17 min
Mobile phase: Buffer A: Water; Buffer B - 80% methanol and 20% Acetonitrile. The gradient is as given in Table 1.
TABLE 1: GRADIENT ELUTION OF MOBILE PHASE
The identity of the product isolated and purified was confirmed as rapamycin through comparison of physic-chemical, spectral and chromatographic properties with those of a sample of authentic rapamycin. The purity of the product was determined by high pressure liquid chromatographic analysis.
The invention will now be described further by way of examples. The examples are merely illustrative of the invention and are not intended to limit the invention in any way.
EXAMPLE 1
BIOMASS SEPARATION
Approximately 1600 liters of rapamycin fermentation broth obtained a large scale fermentation experiment was acidified by addition of dil. sulphuric acid to pH 4.0. The acidified broth containing 5.1% dried solids and 50% of suspended wet solids were fed into a receiver tank. The decanter centrifuge (Fig- 1) consists of centrifuge, conveyer assembly, bowl assembly and frame and casing assembly (ALDEC 20, Alfa laval, Sweden). The feed flow rate was set at lm3/hr and the broth was pumped through a stationary feed inlet tube. The centrifuge was operated with bowl speed of 4400 rpm at 3030 G (centrifugal force). The dense solid particles were pressed outwards against the rotating bowl wall, then the screw conveyer was rotated and solids were discharged into
casing through solid discharge opening. Based on volume, the dam plates were adjusted to receive clarified liquid. Then the clarified liquid was discharged into casing through dam plates. Approximately 1300 liters of clarified liquid was collected and analyzed by HPLC; very little rapamycin activity was detected in the liquid sample. About 350 kilograms of biomass cake thus obtained containing rapamycin was used for solvent extraction to isolate rapamycin.
EXAMPLE 2 RECOVERY OF RAPAMYCIN
350kilogram of biomass cake from example 1 was mixed with l OOOliters of toluene and stirred for 4hrs at 50°C. The extraction process was carried out twice with lOOOliters of toluene. The toluene extract was concentrated to 500 liters. The rich concentrate was washed with 500 liters of 5% sodium bicarbonate Solution, followed by wash with 2X500 L of water. The toluene extract was concentrated to obtain 10 kilogram of oily residue. The oily residue was mixed with 30 liters of acetone. Activated charcoal (5.25grams) was added to this solution. The solution was stirred for 15 minutes at 40°C temperature, filtered and concentrated to obtain oily residue of about 10 kilograms.
EXAMPLE 3
RECOVERY OF RAPAMYCIN
The oily residue (3kg) was applied to a column packed with 30kg of silica gel of 60 - 200 mesh size. The column diameter was 250mm and length was 1.5m. The elution Was carried out with gradient mobile phase of acetone and hexane (90% hexane, 10% acetone - 60 It, 80% hexane, 20% acetone - 60 Its, 70% hexane, 30% acetone - 60 It, 60% hexane, 40% acetone— 150 It). The drug rich fractions were eluted at 60% hexane, 40% acetone ratio. The collected fractions were mixed with 5.25g of activated charcoal. The
solution was stirred, filtered and concentrated under vacuum at 40°C. The residue was dried to obtain 400g of crude powder .The rapamycin purity was 90% with tautomer content 6.5% at 1.1 RRT and other impurities 3.5%.
The HPLC chromatogram for crude rapamycin recovered as above is shown in Fig 3. The details of chromatogram are given in Table 2.
TABLE 2
EXAMPLE 4
PURIFICATION OF RAPAMYCIN
Rapamycin powder (lOg) obtained from example 3 was dissolved in 30ml of isopropyl ether. The solution was stirred, filtered and concentrated at 25°C. The crystals were dried to obtain 9g of white rapamycin powder. The purity of rapamycin powder was 95% with tautomer content of 2.5% at 1.1 RRT and other impurities amounting to 2.5%.
The HPLC chromatogram of rapamycin purified as above using isopropyl ether is shown in Fig 4. The details of chromatogram are given in Table 3.
TABLE 3
EXAMPLE 5 PURIFICATION OF RAPAMYCIN
Rapamycin powder (5g) obtained from example 3 was dissolved in 10ml of diethyl ether. The solution was stirred, filtered and concentrated at 25°C. The crystals were dried to obtain 4.0g of white rapamycin powder. The purity of rapamycin powder was 97% with tautomer content of 1.5% at 1.1 RRT, and other impurities amounting to 1.5%.
The HPLC chromatogram for rapamycin purified as above using diethyl ether is shown in Fig 5. The details of chromatogram are given in Table 4.
TABLE 4
Peak No Retention Time Area % Area RT Ratio Identification
(mins) ^V*sec)
1 13.843 23786 0.488 0.801
2 16.078 26799 0.364 . 0.930
3 16.562 10828 0.203 0.958
4 17.274 15853156 97.266 1.000 Rapamycin
5 18.635 3174 0.264 1.078
6 19.023 381054 1.415 1.101 Tautomer
EXAMPLE 6
CHROMATOGRAPHIC PURIFICATION OF RAPAMYCIN
Rapamycin powder (lOOmg) obtained from example 4 was dissolved in 200ml of acetone. The solution was loaded on a column packed with flash specific media (cartridge from Grace Company, diameter 0.81cm, particle size 40μηι, height 9.6cm). The product was eluted by gradient method.
Mobile phase: Buffer A: Hexane; Buffer B -Ethyl acetate. The gradient is as given in Table 5.
TABLE 5
The product was eluted at a ratio of 60% hexane, 40% acetone and 58% hexane, 42% acetone. The fractions containing pure rapamycin were pooled and concentrated at 15°C. The crystals were filtered and dried. 50mg of rapamycin powder was obtained. . The purity of rapamycin powder was 99% with tautomer content 0.4% at RRT 1.1 and 0.6% of other impurities.
The HPLC chromatograms for rapamycin (reference standard) and that of rapamycin produced in substantially pure form as above using flash chromatography are shown in Fig 2 and Fig 6 respectively. The details of chromatogram as in fig 2 are given in Table 6 and that of fig6 is given in Table 7.
TABLE 6
Peak Retention Time Area % Area RT Ratio Identification
No (mins) ^V*sec)
1 15.687 551902 0.7764 0.912
2 15.900 247455 1.0021 0.924
3 17.195 27225638 95.2694 1.000 Rapamycin
4 18.913 843756 2.6261 1.099 Tautomer
5 19.548 94542 0.326 1.136
TABLE 7
Peak Retention Time Area % Area RT Ratio Identification
No (mins) ^V*sec)
1 15.907 165308 0.400 0.933
2 16.365 38976 0.100 0.960
3 17.033 27042609 99.00 1.000 Rapamycin
4 18.373 32869 0.100 1.078
5 18.732 129663 0.400 1.099 Tautomer
Claims
1. Rapamyciri having a purity of greater than 99% and tautomer content less than 0.5%.
2. Rapamycin as claimed in claim 1 is obtained by a process of isolation and purification.
3. The process of isolation as claimed in claim 2 comprises: a) adjusting pH of fermentation broth to pH 4 with 20% aqueous sulphuric acid b) separation of biomass and acidified broth using decanter centrifuge c) extracting the biomass with suitable solvent mixture and washing the extracted rapamycin with sodium bicarbonate and water
d) concentrating the rapamycin rich extract
e) dissolving the concentrate in a suitable solvent
f) mixing the dissolved product with activated charcoal and filtering
g) concentrating the filtrate
h) chromatographic separation of oily residue using silica gel having a mesh size of about 60-200μηι
i) eluting with a mixture of suitable organic solvent using gradient method.
The process according to claim 3, where in step c) the solvent mixture is toluene and ethyl acetate.
The process according to claim 3, where in step e) the solvent is acetone.
A process according to claim 3, where in step i) the organic solvent is selected from aliphatic hydrocarbons and ketones.
7. A process according to claim 6, where in aliphatic hydrocarbon is selected from n- pentane, n-hexane, n-heptane, cyclo hexane or mixtures thereof.
8. A process according to claim 6, where in ketone is acetone.
9. The process according to claim 3, where in the rapamycin produced thereby has a purity of about 90% with tautomer content of less than 6.5%.
10. A process according to claim 2 wherein the purification process comprises:
j) crystallizing the rapamycin using isopropyl ether or diethyl ether
k) subjecting the crystallized rapamycin to flash chromatography using specialized silica with particle size distribution of about 25 to 45 μπι 1) eluting with a mixture of suitable organic solvent using gradient method
11. The process according to claim 10, where in step j) the crystallized rapamycin produced thereby, has a purity of greater than 96% with tautomer content less than 2%.
12. The process according to claim 10, where in step 1) the organic solvents are selected from aliphatic hydrocarbons and C2-C io esters.
13. The process according to claim 1 1, where in the aliphatic hydrocarbon is n-hexane.
14. The process according to claim 11, where in C2-C[0 ester is ethyl acetate. ,
15. The process according to claim 10 , where in step k) the rapamycin obtained has a purity of greater than 99%, where in rapamycin content is about 99% with the tautomer content less than 0.5% and purity of rapamycin including isomer is about 99.4%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2012/000728 WO2014072984A1 (en) | 2012-11-06 | 2012-11-06 | Improved process for isolation and purification of rapamycin from fermentation broth |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2012/000728 WO2014072984A1 (en) | 2012-11-06 | 2012-11-06 | Improved process for isolation and purification of rapamycin from fermentation broth |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014072984A1 true WO2014072984A1 (en) | 2014-05-15 |
Family
ID=47710244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2012/000728 WO2014072984A1 (en) | 2012-11-06 | 2012-11-06 | Improved process for isolation and purification of rapamycin from fermentation broth |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014072984A1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929992A (en) | 1972-09-29 | 1975-12-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US5508398A (en) | 1993-11-05 | 1996-04-16 | American Home Products Corporation | New extractive process for the recovery of naturally occurring macrolides |
US5616595A (en) | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Process for recovering water insoluble compounds from a fermentation broth |
US20040226501A1 (en) | 2003-03-31 | 2004-11-18 | Vilmos Keri | Crystallization and purification of macrolides |
WO2005019226A1 (en) | 2003-08-26 | 2005-03-03 | Biocon Limited | A process for the recovery of substantially pure tricyclic macrolide |
WO2008056372A1 (en) * | 2006-11-10 | 2008-05-15 | Biocon Limited | A pure form of rapamycin and a process for recovery and purification thereof |
-
2012
- 2012-11-06 WO PCT/IN2012/000728 patent/WO2014072984A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929992A (en) | 1972-09-29 | 1975-12-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US5508398A (en) | 1993-11-05 | 1996-04-16 | American Home Products Corporation | New extractive process for the recovery of naturally occurring macrolides |
US5616595A (en) | 1995-06-07 | 1997-04-01 | Abbott Laboratories | Process for recovering water insoluble compounds from a fermentation broth |
US20040226501A1 (en) | 2003-03-31 | 2004-11-18 | Vilmos Keri | Crystallization and purification of macrolides |
WO2005019226A1 (en) | 2003-08-26 | 2005-03-03 | Biocon Limited | A process for the recovery of substantially pure tricyclic macrolide |
WO2008056372A1 (en) * | 2006-11-10 | 2008-05-15 | Biocon Limited | A pure form of rapamycin and a process for recovery and purification thereof |
Non-Patent Citations (1)
Title |
---|
J.CHROMATOGRAPHY, vol. 149, 1978, pages 417 - 419 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005522460A (en) | Method and system for separation and purification of at least one narcotic alkaloid using reverse phase preparative chromatography | |
CN107501045B (en) | Method for separating and purifying butanetriol from fermentation liquor by using macroporous adsorption resin | |
JP4261365B2 (en) | Method for extracting macrolides from biological materials | |
WO2008056372A1 (en) | A pure form of rapamycin and a process for recovery and purification thereof | |
EP2647643B1 (en) | Procedure for the purification of tiacumicin b | |
EP1558622B1 (en) | Method of purifying macrolides | |
WO2005019226A1 (en) | A process for the recovery of substantially pure tricyclic macrolide | |
WO2014072984A1 (en) | Improved process for isolation and purification of rapamycin from fermentation broth | |
KR20080039970A (en) | Purification of tacrolimus on supports of vegetable origin | |
WO2007013017A1 (en) | A process for purification of macrolides | |
US7452692B2 (en) | Method for extracting a macrolide from biomatter | |
CN105819444A (en) | Composite type activated carbon and application thereof in purifying tacrolimus | |
CN101031654A (en) | Process for isolation of crystalline tacrolimus | |
CN113912624B (en) | Tacrolimus separation and purification method | |
CN111909176B (en) | Method for recovering ascomycin and tacrolimus 8-propyl analogue from tacrolimus separation waste liquid | |
WO2022262591A1 (en) | Method for purifying ansamitocin p-3 | |
KR100259396B1 (en) | Method for mass production of high purity taxol from taxus genus plant | |
KR100259395B1 (en) | Method for mass production of high purity taxol form taxus genus plant | |
JP2023028473A (en) | Method for producing everolimus | |
DK165835B (en) | PROCEDURE FOR INSULATING ANTIBIOTICS S541 COMPOUNDS | |
KR20070030923A (en) | Method for extracting a macrolide from biomatter | |
CN116063316A (en) | Method for purifying oligomycin A | |
WO2008059516A2 (en) | Process for purification of macrolides | |
CN108864257A (en) | High purity cyclosporin A and preparation method thereof | |
KIM | A NOVEL PURIFICATION FOR PACLITAXEL FROM PLANT CELL CULTURES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12823210 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12823210 Country of ref document: EP Kind code of ref document: A1 |